List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1560399/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association between psoriasis and asthma among United States adults in the 2009-2014 National Health and Nutrition Examination Survey. Journal of the American Academy of Dermatology, 2022, 86, 709-712.	1.2	3
2	Disease burden, symptoms, and use of analgesics in patients with psoriasis withÂor without psoriatic arthritis: AÂcross-sectional study. Journal of the American Academy of Dermatology, 2022, 86, 590-597.	1.2	8
3	Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab. Journal of Dermatological Treatment, 2022, 33, 2503-2509.	2.2	10
4	The risk of COVID-19 infection in patients with atopic dermatitis: A retrospective cohort study. Journal of the American Academy of Dermatology, 2022, 86, 243-245.	1.2	17
5	Family burden of hospitalâ€managed pediatric atopic dermatitis: A nationwide registryâ€based study. Pediatric Allergy and Immunology, 2022, 33, .	2.6	5
6	Factors associated with ocular surface disease and severity in adults with atopic dermatitis: a nationwide survey. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 592-601.	2.4	10
7	Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 403-412.	2.4	10
8	Drug Survival of Biologics in Patients With Hidradenitis Suppurativa. JAMA Dermatology, 2022, 158, 184.	4.1	18
9	Successful treatment of psoriasis with adalimumab induced no changes in the gut microbiota. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	2
10	Association of maternal psoriasis and small for gestational age or preterm birth: A nationwide matched cohort study in 69 080 singleton infants. Clinical and Experimental Dermatology, 2022, , .	1.3	0
11	Rapid improvement of idiopathic aphthous ulcers with oral roflumilast therapy. British Journal of Dermatology, 2022, 187, 258-259.	1.5	9
12	Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries. Seminars in Arthritis and Rheumatism, 2022, 53, 151979.	3.4	32
13	Patient characteristics and disease burden of alopecia areata in the Danish Skin Cohort. BMJ Open, 2022, 12, e053137.	1.9	9
14	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. JAMA Dermatology, 2022, 158, 561.	4.1	12
15	Increased prevalence of sleep disturbance in psoriatic arthritis is associated with inflammatory and non-inflammatory measures. Scandinavian Journal of Rheumatology, 2022, , 1-9.	1.1	6
16	Amplicon sequencing demonstrates comparable follicular mycobiomes in patients with hidradenitis suppurativa compared with healthy controls. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	3
17	Patients with psoriasis have a dysbiotic taxonomic and functional gut microbiota*. British Journal of Dermatology, 2022, 187, 89-98.	1.5	17
18	Incidence, prevalence and risk of acne in adolescent and adult patients with atopic dermatitis: a matched cohort study. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 890-896.	2.4	13

#	Article	IF	CITATIONS
19	Prevalence and characterization of treatmentâ€refractory psoriasis and superâ€responders to biologic treatment: a nationwide study. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1284-1291.	2.4	18
20	A nationwide population-based cohort study of the incidence of severe and rare infections among adults with psoriasis in Denmark. British Journal of Dermatology, 2022, 187, 353-363.	1.5	6
21	Delay in diagnosis and treatment of patients with psoriasis – a populationâ€based crossâ€sectional study. British Journal of Dermatology, 2022, , .	1.5	3
22	Assessment of Frequency of Rosacea Subtypes in Patients With Rosacea. JAMA Dermatology, 2022, 158, 617.	4.1	13
23	Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?. Clinical and Experimental Dermatology, 2022, 47, 1585-1586.	1.3	4
24	Psoriasis and adverse pregnancy outcomes: A nationwide case-control study in 491,274 women in Denmark. JAAD International, 2022, 7, 146-155.	2.2	7
25	Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: <i>post hoc</i> analysis of 5â€year data from <scp>reSURFACE</scp> 1 and <scp>reSURFACE</scp> 2. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1774-1783.	2.4	7
26	Killing all the birds with one drug – is oral roflumilast a novel treatment option for psoriasis?. Journal of Dermatological Treatment, 2022, 33, 2782-2783.	2.2	1
27	Agreement and Correlation Between Different Topical Corticosteroid Potency Classification Systems. JAMA Dermatology, 2022, 158, 796.	4.1	6
28	The road to biologics in patients with hidradenitis suppurativa: a nationwide drug utilization study. British Journal of Dermatology, 2022, 187, 523-530.	1.5	5
29	Rapid clearing of refractory nummular dermatitis with oral roflumilast therapy. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	7
30	Real-world dose adjustments of biologic treatments in psoriasis and their economic impact: a Swedish national population study. Clinical and Experimental Dermatology, 2022, 47, 1968-1975.	1.3	2
31	Absolute and Relative Risk of New-Onset Psoriasis Associated With Tumor Necrosis Factor-α Inhibitor Treatment in Patients With Immune-Mediated Inflammatory Diseases. JAMA Dermatology, 2022, 158, 997.	4.1	4
32	Considerable improvement in hidradenitis suppurativa with oral roflumilast therapy. British Journal of Dermatology, 2022, 187, 813-815.	1.5	13
33	Adults with concomitant atopic dermatitis and asthma have more frequent urgent healthcare utilization and less frequent scheduled followâ€up visits than adults with atopic dermatitis or asthma only: a nationwide cohort study. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 2406-2413.	2.4	2
34	Reply to: "Comment on †Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis'― Journal of the American Academy of Dermatology, 2021, 85, e379.	1.2	3
35	Bidirectional association between atopic dermatitis, conjunctivitis, and other ocular surface diseases: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2021, 85, 453-461.	1.2	21
36	Placebo Response in Phase 3 Trials of Systemic Therapies for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis. Dermatology, 2021, 237, 158-165.	2.1	3

#	Article	IF	CITATIONS
37	Prevalence of asthma in patients with atopic dermatitis: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2021, 84, 471-478.	1.2	37
38	Risk of systemic infections in adults with atopic dermatitis: A nationwide cohort study. Journal of the American Academy of Dermatology, 2021, 84, 290-299.	1.2	13
39	Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2021, 84, 130-138.	1.2	20
40	Disease severity and trigger factors in Danish children with atopic dermatitis: a nationwide study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 948-957.	2.4	11
41	Healthcare utilization in Danish children with atopic dermatitis and parental topical corticosteroid phobia. Pediatric Allergy and Immunology, 2021, 32, 331-341.	2.6	14
42	Comorbidities of alopecia areata: a populationâ€based cohort study. Clinical and Experimental Dermatology, 2021, 46, 651-656.	1.3	20
43	Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study. Journal of the American Academy of Dermatology, 2021, 84, 930-937.	1.2	16
44	Prevalence of psoriasis among adults in the US 2009-2010 and 2013-2014 National Health and Nutrition Examination Surveys. Journal of the American Academy of Dermatology, 2021, 84, 767-769.	1.2	17
45	Response to Biologics During the First Six Months of Therapy in Biologic-naÃ⁻ve Patients with Psoriasis Predicts Risk of Disease Flares: A Danish Nationwide Study. Acta Dermato-Venereologica, 2021, 101, adv00357.	1.3	7
46	Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial. Cephalalgia, 2021, 41, 731-748.	3.9	19
47	Treatment Patterns in Danish Patients with Atopic Dermatitis Before and After Hospital Referral. Dermatology and Therapy, 2021, 11, 499-512.	3.0	10
48	Subtype-Specific Off-Label Treatment of Rosacea. Case Reports in Dermatology, 2021, 13, 121-128.	0.8	4
49	Bariatric Surgery and Risk of New-onset Inflammatory Bowel Disease: A Nationwide Cohort Study. Journal of Crohn's and Colitis, 2021, 15, 1474-1480.	1.3	13
50	Risk of systemic infections requiring hospitalization in children with atopic dermatitis: a Danish retrospective nationwide cohort study*. British Journal of Dermatology, 2021, 185, 119-129.	1.5	3
51	Association between hospitalâ€diagnosed atopic dermatitis and psychiatric disorders and medication use in childhood*. British Journal of Dermatology, 2021, 185, 91-100.	1.5	14
52	Association of Potent and Very Potent Topical Corticosteroids and the Risk of Osteoporosis and Major Osteoporotic Fractures. JAMA Dermatology, 2021, 157, 275.	4.1	42
53	Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies – A Danish population-based cohort study. Journal of Autoimmunity, 2021, 118, 102613.	6.5	41
54	Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review. American Journal of Clinical Dermatology, 2021, 22, 425-442.	6.7	55

#	Article	IF	CITATIONS
55	Comorbidities, socioeconomic status, drug use, and health care consumption in Danish women with psoriasis: A nationwide cross-sectional study. International Journal of Women's Dermatology, 2021, 7, 246-258.	2.0	7
56	Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis. JAMA Dermatology, 2021, 157, 676.	4.1	24
57	Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: A population-based study. Journal of the American Academy of Dermatology, 2021, 84, 1636-1643.	1.2	34
58	Infusion of Pituitary Adenylate Cyclase–Activating Polypeptide-38 in Patients with Rosacea Induces Flushing and Facial Edema that Can Be Attenuated by Sumatriptan. Journal of Investigative Dermatology, 2021, 141, 1687-1698.	0.7	11
59	Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderateâ€toâ€severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e709-e711.	2.4	2
60	Increased allâ€cause mortality in concomitant atopic dermatitis and asthma: A nationwide registryâ€based study. Clinical and Experimental Allergy, 2021, 51, 1207-1217.	2.9	0
61	Rhinitis prevalence and association with atopic dermatitis. Annals of Allergy, Asthma and Immunology, 2021, 127, 49-56.e1.	1.0	15
62	Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. American Journal of Clinical Dermatology, 2021, 22, 693-707.	6.7	67
63	Awareness and Expectations Surrounding Family Planning and Pregnancy Among Danish Patients with Chronic Inflammatory Disease of the Skin or Joints: Results from an Online Survey. Rheumatology and Therapy, 2021, 8, 1419-1433.	2.3	1
64	Limitations of Using Questionnaires for Assessing the Prevalence of Psoriasis and Atopic Dermatitis Among Adults. JAMA Dermatology, 2021, 157, 971.	4.1	3
65	Reply to "Correspondence to †Association between psoriasis and asthma among United States adults in the 2009-2014 National Health and Nutrition Examination Survey'― Journal of the American Academy of Dermatology, 2021, , .	1.2	0
66	Complete clearance of severe plaque psoriasis with 24 weeks of oral roflumilast therapy. British Journal of Dermatology, 2021, 185, 1251-1252.	1.5	12
67	Global Prevalence of Young-Onset Dementia. JAMA Neurology, 2021, 78, 1080.	9.0	124
68	Modeling the optimal sequence of biologic therapies in plaque psoriasis in Spain. Journal of Medical Economics, 2021, 24, 1134-1142.	2.1	5
69	Validation of claims-based indicators used to identify flare-ups in inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110048.	3.2	4
70	Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study. Acta Dermato-Venereologica, 2021, 101, adv00579.	1.3	16
71	Is Real-world Evidence Really Real?. Journal of Rheumatology, 2021, , jrheum.211044.	2.0	1
72	Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort study. Rheumatology Advances in Practice, 2021, 5, rkab076.	0.7	4

#	Article	IF	CITATIONS
73	No association between omalizumab use and risk of cancer: a nationwide registryâ€based cohort study. British Journal of Dermatology, 2021, , .	1.5	6
74	Symptom burden of patients with moderate-to-severe atopic dermatitis. European Journal of Dermatology, 2021, 31, 752-758.	0.6	3
75	Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience. Journal of Dermatological Treatment, 2020, 31, 794-800.	2.2	26
76	Drug survival of guselkumab for psoriasis in a real-world setting: a single-center retrospective chart review. Journal of Dermatological Treatment, 2020, 31, 342-343.	2.2	13
77	Clinical characteristics, symptoms and burden of psoriasis and atopic dermatitis in adults. British Journal of Dermatology, 2020, 183, 128-138.	1.5	46
78	Pain severity and use of analgesic medication in adults with atopic dermatitis: a crossâ€sectional study. British Journal of Dermatology, 2020, 182, 1430-1436.	1.5	19
79	Use of topical calcipotriol for identification of patients with psoriasis in administrative healthcare data—a validation study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e90-e91.	2.4	6
80	Relationship Between Fatigue and Inflammation, Disease Duration, and Chronic Pain in Psoriatic Arthritis: An Observational DANBIO Registry Study. Journal of Rheumatology, 2020, 47, 548-552.	2.0	24
81	Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease—A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis, 2020, 14, 351-360.	1.3	58
82	Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses. Dermatology and Therapy, 2020, 10, 73-86.	3.0	38
83	The Association Between Season of Birth and Atopic Dermatitis in the Northern Hemisphere: AÂSystematic Review and Meta-Analysis. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 674-680.e5.	3.8	28
84	Systematic review on rapidity of onset of action for interleukinâ€17 and interleukinâ€23 inhibitors for psoriasis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 39-46.	2.4	36
85	How does parental history of atopic disease predict the risk of atopic dermatitis in a child? AÂsystematic review and meta-analysis. Journal of Allergy and Clinical Immunology, 2020, 145, 1182-1193.	2.9	39
86	Placebo response in phase 2 and 3 trials of systemic and biological therapies for atopic dermatitis—a systematic review and metaâ€analysis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1143-1150.	2.4	10
87	Adverse events with ILâ€17 and ILâ€23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and metaâ€analysis of phase III studies. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1151-1160.	2.4	59
88	Treatment of adult atopic dermatitis patients according to disease characteristics and demographics. Dermatologic Therapy, 2020, 33, e14439.	1.7	4
89	Cohort profile: COpenhagen ROsacea COhort (COROCO) and COpenhagen MIgraine COhort (COMICO). BMJ Open, 2020, 10, e039445.	1.9	5
90	Risk of skin cancer in patients with vitiligo in Denmark: A nationwide cohort study. JAAD International, 2020, 1, 31-38.	2.2	6

#	Article	IF	CITATIONS
91	Association between head and neck cancer and sexually transmitted diseases: a Danish nationwide, case-control study. Acta Oto-Laryngologica, 2020, 140, 608-612.	0.9	4
92	Strengths and limitations of the United Kingdom Working Party criteria for atopic dermatitis in adults. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1764-1772.	2.4	21
93	Do we need to fear methotrexate?. British Journal of Dermatology, 2020, 183, 608-609.	1.5	0
94	The role of the interleukinâ€23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1695-1706.	2.4	57
95	Incidences of different cancer types in dermatomyositis, polymyositis and dermatopolymyositis: results of a registry analysis. British Journal of Dermatology, 2020, 183, 186-188.	1.5	4
96	Dosage Adjustments in Patients With Psoriasis on Etanercept: A Retrospective Chart Review. Journal of Psoriasis and Psoriatic Arthritis, 2020, 5, 52-53.	0.7	1
97	Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis. JAMA Dermatology, 2020, 156, 421.	4.1	123
98	Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort. BMC Dermatology, 2020, 20, 3.	2.1	43
99	Investigating the Link between Psoriasis and Cardiovascular Disease: Current Evidence, Therapeutic Implications and Perspectives. Current Vascular Pharmacology, 2020, 18, 592-609.	1.7	6
100	FRI0592â€IMPACT OF INDIVIDUAL SYMPTOMS OF PSORIATIC ARTHRITIS ON PHYSICAL COMPONENT SCORE AN MENTAL COMPONENT SCORE OF SF-36 AS A MEASURE OF HEALTH RELATED QUALITY OF LIFE (QOL): AN OBSERVATIONAL COHORT STUDY. Annals of the Rheumatic Diseases, 2020, 79, 901.1-902.	ND 0.9	0
101	PARE0024â€AWARENESS ABOUT FAMILY PLANNING AND PREGNANCY EXPECTATION AMONG PATIENTS WITH CHRONIC INFLAMMATORY DISEASE OF THE SKIN OR JOINTS. Annals of the Rheumatic Diseases, 2020, 79, 1297.1-1298.	0.9	0
102	Rosacea and Cardiovascular Comorbidities. Updates in Clinical Dermatology, 2020, , 105-112.	0.1	1
103	Rosacea and Cancer. Updates in Clinical Dermatology, 2020, , 113-120.	0.1	0
104	Rosacea and Gastrointestinal Comorbidities. Updates in Clinical Dermatology, 2020, , 89-98.	0.1	0
105	Low-dose Naltrexone Therapy for Psoriasis. International Journal of Pharmaceutical Compounding, 2020, 24, 94-96.	0.0	2
106	Drug survival of secukinumab for psoriasis in a real-world setting. Journal of Dermatological Treatment, 2019, 30, 150-151.	2.2	14
107	Comparing apples, oranges and atopic dermatitis. British Journal of Dermatology, 2019, 181, 1125-1126.	1.5	0
108	Seborrhoeic dermatitis – understood or understudied?. British Journal of Dermatology, 2019, 181, 659-659.	1.5	3

7

#	Article	IF	CITATIONS
109	Chronologic order of appearance of immune-mediated inflammatory diseases relative to diagnosis of psoriasis. Journal of the American Academy of Dermatology, 2019, 81, 1283-1291.	1.2	15
110	Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitis. Journal of the American Academy of Dermatology, 2019, 81, 943-949.	1.2	26
111	Incidence of Immune-Mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark. Clinical Gastroenterology and Hepatology, 2019, 17, 2704-2712.e3.	4.4	54
112	The many faces of rosacea: liberal diagnostic criteria have ramifications on disease prevalence and accuracy. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e426-e427.	2.4	2
113	Real-world drug survival of ixekizumab for psoriasis. Journal of the American Academy of Dermatology, 2019, 81, 270-272.	1.2	7
114	Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology, 2019, 81, 173-178.	1.2	55
115	Chronic urticaria – bad to the bone?. British Journal of Dermatology, 2019, 180, 979-979.	1.5	0
116	Prevalence and characteristics of psoriasis in Denmark: findings from the Danish skin cohort. BMJ Open, 2019, 9, e028116.	1.9	52
117	Characteristics and prevalence of plaque psoriasis in patients with palmoplantar pustulosis. British Journal of Dermatology, 2019, 181, 976-982.	1.5	22
118	Burden and Disease Characteristics of Patients with Psoriatic Arthritis: A Population-based Cross-sectional Study. Journal of Rheumatology, 2019, 46, 716-720.	2.0	11
119	Association Between Topical Corticosteroid Use and Type 2 Diabetes in Two European Population-Based Adult Cohorts. Diabetes Care, 2019, 42, 1095-1103.	8.6	28
120	Association between parental autoimmune disease and atopic dermatitis in their offspring: a matched case–control study. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1143-1151.	2.4	5
121	Atopic dermatitis and cancer in solid organs: a systematic review and metaâ€analysis. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e81-e82.	2.4	8
122	Risk of firstâ€ŧime and recurrent depression in patients with psoriasis: a populationâ€based cohort study. British Journal of Dermatology, 2019, 180, 116-121.	1.5	32
123	Demographics, healthcare utilization and drug use in children and adults with atopic dermatitis in Denmark: aÂpopulationâ€based crossâ€sectional study. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1133-1142.	2.4	28
124	Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasis—A Nationwide 20-Year Cohort Study. Journal of Investigative Dermatology, 2019, 139, 316-323.	0.7	35
125	Prevalence of contact allergy in the general population: A systematic review and metaâ€∎nalysis. Contact Dermatitis, 2019, 80, 77-85.	1.4	200
126	Exploring the association between parental psychiatric disease and childhood atopic dermatitis: a matched case–control study. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 725-734.	2.4	10

#	Article	lF	CITATIONS
127	Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. Journal of the American Academy of Dermatology, 2019, 80, 251-265.e19.	1.2	362
128	Pregnancy complications, treatment characteristics and birth outcomes in women with atopic dermatitis in Denmark. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 577-587.	2.4	31
129	Validation of Psoriasis Diagnoses in the Danish National Patient Register. Acta Dermato-Venereologica, 2019, 99, 1037-1038.	1.3	17
130	Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study. Acta Dermato-Venereologica, 2019, 99, 1224-1230.	1.3	21
131	Risk for appendicitis, cholecystitis, or diverticulitis in patients with psoriasis. Cutis, 2019, 103, 175-179;E1;E2.	0.3	1
132	Effects of Biologic Therapy on Cardiovascular Disease in Psoriasis. Current Dermatology Reports, 2018, 7, 37-42.	2.1	4
133	Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review. Journal of Dermatological Treatment, 2018, 29, 671-675.	2.2	13
134	Incidence and prevalence of rosacea: a systematic review and meta-analysis. British Journal of Dermatology, 2018, 179, 282-289.	1.5	166
135	Drug survival of secukinumab for moderate-to-severe plaque psoriasis: reply from authors. British Journal of Dermatology, 2018, 179, 222-223.	1.5	0
136	Incidence of pediatric atopic dermatitis following thymectomy: A Danish register study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1741-1743.	5.7	8
137	Antiâ€inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1320-1326.	2.4	39
138	Treatment changes in patients with psoriasis on etanercept or adalimumab: a retrospective chart review. Journal of Dermatological Treatment, 2018, 29, 664-665.	2.2	1
139	Atopic dermatitis and alcohol use – a metaâ€analysis and systematic review. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1238-1245.	2.4	26
140	Dosage adjustments in patients with psoriasis on adalimumab – a retrospective chart review. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e292-e293.	2.4	2
141	Incident Heart Failure in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study. Journal of the American Heart Association, 2018, 7, .	3.7	40
142	Cause-specific mortality in adults with atopic dermatitis. Journal of the American Academy of Dermatology, 2018, 78, 506-510.	1.2	22
143	Psoriasis and risk of malignant lymphoma: a population-based cohort study. British Journal of Dermatology, 2018, 178, 1435-1436.	1.5	14
144	The effects of season and weather on healthcare utilization among patients with atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1745-1753.	2.4	30

#	Article	IF	CITATIONS
145	lxekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3. Journal of the American Academy of Dermatology, 2018, 79, 104-109.e8.	1.2	40
146	The association between atopic dermatitis and hand eczema: a systematic review and meta-analysis. British Journal of Dermatology, 2018, 178, 879-888.	1.5	80
147	Atopic dermatitis 2017: where we were 10–15 years ago in psoriasis. Journal of Dermatological Treatment, 2018, 29, 100-101.	2.2	2
148	Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 214-220.	5.7	129
149	Differential disease burden and treatment patterns among adults with psoriasis and atopic dermatitis seen in hospital vs. private clinics. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e23-e25.	2.4	4
150	Validation of psoriasis severity classification based on use of topical or systemic treatment. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e4-e5.	2.4	15
151	Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?. American Journal of Clinical Dermatology, 2018, 19, 1-13.	6.7	56
152	Increased Suicide Risk in Patients with Hidradenitis Suppurativa. Journal of Investigative Dermatology, 2018, 138, 52-57.	0.7	134
153	Risk of uncommon cancers in patients with psoriasis: a Danish nationwide cohort study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 601-605.	2.4	9
154	The relationship between migraine and rosacea: Systematic review and meta-analysis. Cephalalgia, 2018, 38, 1387-1398.	3.9	24
155	The value and pitfalls of biologics registries for psoriasis. British Journal of Dermatology, 2018, 178, 301-302.	1.5	3
156	Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. British Journal of Dermatology, 2018, 178, 509-519.	1.5	239
157	The association with cardiovascular disease and type 2 diabetes in adults with atopic dermatitis: a systematic review and meta-analysis. British Journal of Dermatology, 2018, 178, 1272-1279.	1.5	49
158	Poor agreement in questionnaireâ€based diagnostic criteria for adult atopic dermatitis is a challenge when examining cardiovascular comorbidity. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 923-931.	5.7	21
159	Impact of age and sex on the incidence and prevalence of psoriatic arthritis. Annals of the Rheumatic Diseases, 2018, 77, e19-e19.	0.9	4
160	Risk of aortic aneurysm in patients with psoriasis: a retrospective cohort study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e54-e56.	2.4	4
161	Vasomotor reactions in the face and head of patients with migraine. Cephalalgia Reports, 2018, 1, 251581631879054.	0.7	2
162	The good, the bad and the malignant. British Journal of Dermatology, 2018, 179, 809-810.	1.5	0

#	Article	IF	CITATIONS
163	Duration of psoriatic arthritis as a risk factor for myocardial infarction. Rheumatology Advances in Practice, 2018, 2, rky011.	0.7	3
164	Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab. Acta Dermato-Venereologica, 2018, 98, 335-339.	1.3	22
165	Cardiovascular disease and atopic dermatitis: epidemiological strengths and limitations. British Journal of Dermatology, 2018, 179, 1014-1015.	1.5	3
166	Duration of Psoriatic Skin Disease as Risk Factor for Subsequent Onset of Psoriatic Arthritis. Acta Dermato-Venereologica, 2018, 98, 546-550.	1.3	16
167	Adverse events associated with apremilast use and withdrawal for psoriasis in a realâ€world setting. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e393-e394.	2.4	20
168	Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2018, 79, 448-456.e30.	1.2	210
169	Increased risk of depression in patients with cutaneous lupus erythematosus and systemic lupus erythematosus: a Danish nationwide cohort study. British Journal of Dermatology, 2018, 179, 1095-1101.	1.5	25
170	Erectile Dysfunction in Male Adults with Atopic Dermatitis and Psoriasis. Journal of Sexual Medicine, 2017, 14, 380-386.	0.6	18
171	Prevalence and Risk of Inflammatory BowelÂDisease in Patients with HidradenitisÂSuppurativa. Journal of Investigative Dermatology, 2017, 137, 1060-1064.	0.7	68
172	Rosacea and risk of cancer in Denmark. Cancer Epidemiology, 2017, 47, 76-80.	1.9	22
173	The risk of depression, suicidal ideation and suicide attempt in patients with psoriasis, psoriatic arthritis or ankylosing spondylitis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1168-1175.	2.4	89
174	Filaggrin lossâ€ofâ€function mutations, atopic dermatitis and risk of actinic keratosis: results from two crossâ€sectional studies. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1038-1043.	2.4	14
175	Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderateâ€toâ€severe plaque psoriasis – nationwide results from the <scp>DERMBIO</scp> registry. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1183-1187.	2.4	21
176	Evidenceâ€based management of rosacea. British Journal of Dermatology, 2017, 176, 300-301.	1.5	0
177	Treatment history of patients receiving biologic therapy for psoriasis – a Danish nationwide study. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e362-e363.	2.4	15
178	Newâ€onset inflammatory bowel disease in adults with atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e363-e365.	2.4	8
179	Assessment of major comorbidities in adults with atopic dermatitis using the Charlson comorbidity index. Journal of the American Academy of Dermatology, 2017, 76, 1088-1092.e1.	1.2	30
180	Birth Outcomes in Children Fathered by Men Treated with Immunosuppressant Drugs before Conception—A Danish Population-Based Cohort Study. Journal of Investigative Dermatology, 2017, 137, 1790-1792.	0.7	11

#	Article	IF	CITATIONS
181	Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. Annals of the Rheumatic Diseases, 2017, 76, 1591-1597.	0.9	52
182	Update on Comorbidities in Psoriasis. Current Dermatology Reports, 2017, 6, 129-136.	2.1	1
183	Sites of recurrence in patients following clearance of psoriasis with biologic therapy. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e297-e298.	2.4	3
184	Comorbidities of Atopic Dermatitis: Beyond Rhinitis and Asthma. Current Dermatology Reports, 2017, 6, 35-41.	2.1	55
185	Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis. New England Journal of Medicine, 2017, 376, 2092-2093.	27.0	24
186	Rosacea is associated with Helicobacter pylori: a systematic review and metaâ€analysis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 2010-2015.	2.4	55
187	The association between psoriasis and coeliac disease. British Journal of Dermatology, 2017, 177, e329-e330.	1.5	13
188	Burden of respiratory comorbidities in patients with atopic dermatitis and psoriasis. British Journal of Dermatology, 2017, 177, e145-e146.	1.5	9
189	Association between atopic dermatitis and contact sensitization: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2017, 77, 70-78.	1.2	107
190	Incidence and Prognosis of Psoriasis and Psoriatic Arthritis in Patients Undergoing Bariatric Surgery. JAMA Surgery, 2017, 152, 344.	4.3	69
191	Increased global arterial and subcutaneous adipose tissue inflammation in patients with moderate-to-severe psoriasis. British Journal of Dermatology, 2017, 176, 732-740.	1.5	41
192	Getting tired of psoriasis?. British Journal of Dermatology, 2017, 177, 899-900.	1.5	1
193	Cardiometabolic disease in atopic dermatitis: the heart of the matter. British Journal of Dermatology, 2017, 177, 898-899.	1.5	1
194	The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. Journal of the American Academy of Dermatology, 2017, 77, 650-656.e3.	1.2	81
195	A critical eye on registry data in psoriasis. British Journal of Dermatology, 2017, 177, 245-246.	1.5	9
196	Herpes zoster in psoriasis patients treated with tofacitinib. Journal of the American Academy of Dermatology, 2017, 77, 302-309.	1.2	57
197	Limited incremental effect of inflammatory bowel disease on risk of comorbidities in patients with psoriasis. Journal of Dermatology, 2017, 44, 1176-1177.	1.2	1
198	Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis. Journal of the American Academy of Dermatology, 2017, 77, 280-286.e1.	1.2	110

#	Article	IF	CITATIONS
199	Autoimmune diseases in adults with atopic dermatitis. Journal of the American Academy of Dermatology, 2017, 76, 274-280.e1.	1.2	99
200	Adult atopic dermatitis and the risk of type 2 diabetes. Journal of Allergy and Clinical Immunology, 2017, 139, 1057-1059.	2.9	34
201	Ten-year mortality is increased after hospitalization for atopic dermatitis compared with the general population, but reduced compared with psoriasis. Journal of the American Academy of Dermatology, 2017, 76, 98-105.	1.2	12
202	Prevalence and risk of migraine in patients with rosacea: A population-based cohort study. Journal of the American Academy of Dermatology, 2017, 76, 454-458.	1.2	36
203	Anxiety, depression and suicide in patients with prurigo nodularis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e106-e107.	2.4	53
204	Risk of periodontitis in patients with psoriasis and psoriatic arthritis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 288-293.	2.4	55
205	Rosacea and gastrointestinal disorders: a populationâ€based cohort study. British Journal of Dermatology, 2017, 176, 100-106.	1.5	117
206	Psychiatric comorbidities in children and adolescents with psoriasis: a population-based cohort study. British Journal of Dermatology, 2017, 177, 551-553.	1.5	16
207	Prevalence of comorbidity and associated risk factors in adults with atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 783-791.	5.7	68
208	Patients with hidradenitis suppurativa have no increased risk of Alzheimer disease. British Journal of Dermatology, 2017, 177, 273-275.	1.5	21
209	OP0112â€In psoriatic arthritis fatigue is driven by inflammation, disease duration, and chronic pain: an observational danbio registry study. , 2017, , .		0
210	Gallstone Risk in Adult Patients with Atopic Dermatitis and Psoriasis: Possible Effect of Overweight and Obesity. Acta Dermato-Venereologica, 2017, 97, 627-631.	1.3	13
211	Autoimmune Disease in Children and Adolescents with Psoriasis: A Cross-sectional Study in Denmark. Acta Dermato-Venereologica, 2017, 97, 1225-1229.	1.3	20
212	Cardiovascular Risk is not Increased in Patients with Chronic Urticaria: A Retrospective Population-based Cohort Study. Acta Dermato-Venereologica, 2017, 97, 261-262.	1.3	11
213	Incidence and Prevalence of Psoriasis in Denmark. Acta Dermato-Venereologica, 2017, 97, 808-812.	1.3	68
214	Risk of Myocardial Infarction in Patients with Psoriasis and Psoriatic Arthritis: A Nationwide Cohort Study. Acta Dermato-Venereologica, 2017, 97, 819-824.	1.3	39
215	Skin disorders in Parkinson's disease: potential biomarkers and risk factors. Clinical, Cosmetic and Investigational Dermatology, 2017, Volume 10, 87-92.	1.8	45
216	The role of biologic therapy for psoriasis in cardiovascular risk reduction. Cutis, 2017, 99, 78-79.	0.3	2

#	Article	IF	CITATIONS
217	Psoriasis and Sleep Apnea: A Danish Nationwide Cohort Study. Journal of Clinical Sleep Medicine, 2016, 12, 663-671.	2.6	33
218	Effect of Biological Therapy on the Risk of Sleep Apnea in Patients with Psoriasis. Journal of Clinical Sleep Medicine, 2016, 12, 1311-1311.	2.6	0
219	Impact of Depression on Risk of Myocardial Infarction, Stroke and Cardiovascular Death in Patients with Psoriasis: A Danish Nationwide Study. Acta Dermato-Venereologica, 2016, 96, 218-221.	1.3	34
220	Prognosis after Hospitalization for Erythroderma. Acta Dermato-Venereologica, 2016, 96, 959-962.	1.3	4
221	Decreased risk of hypertension in subjects with skin cancers – another salubrious effect of sunlight?. Journal of the European Academy of Dermatology and Venereology, 2016, 30, e176-e177.	2.4	1
222	Psoriasis and New-onset Depression: A Danish Nationwide Cohort Study. Acta Dermato-Venereologica, 2016, 96, 39-42.	1.3	53
223	Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. British Journal of Dermatology, 2016, 175, 487-492.	1.5	114
224	Risk of self-harm and nonfatal suicide attempts, and completed suicide in patients with psoriasis: a population-based cohort study. British Journal of Dermatology, 2016, 175, 493-500.	1.5	46
225	Risk of myocardial infarction, ischemic stroke, and cardiovascular death in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology, 2016, 138, 310-312.e3.	2.9	98
226	Management of cardiovascular disease in patients with psoriasis. Expert Opinion on Pharmacotherapy, 2016, 17, 1509-1516.	1.8	8
227	Nationwide Study on the Risk of Abdominal Aortic Aneurysms in Patients With Psoriasis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1043-1048.	2.4	20
228	Increased Risk of Autoimmune Hepatitis in Patients with Psoriasis: A Danish Nationwide Cohort Study. Journal of Investigative Dermatology, 2016, 136, 1515-1517.	0.7	14
229	Predictors of drug survival for tumour necrosis factor-α and interleukin 12/23 antagonists in psoriasis. British Journal of Dermatology, 2016, 175, 247-248.	1.5	2
230	Nationwide Assessment of Cause-Specific Mortality in Patients with Rosacea: A Cohort Study in Denmark. American Journal of Clinical Dermatology, 2016, 17, 673-679.	6.7	22
231	Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis. Journal of the American Academy of Dermatology, 2016, 75, 897-905.	1.2	38
232	Association Between Rosacea and Parkinson Disease—Reply. JAMA Neurology, 2016, 73, 1159.	9.0	1
233	Assessment of the risk of cardiovascular disease in patients with rosacea. Journal of the American Academy of Dermatology, 2016, 75, 336-339.	1.2	47
234	Fumarates for treatment of psoriasis. British Journal of Dermatology, 2016, 175, 857-857.	1.5	0

#	Article	IF	CITATIONS
235	Patients with rosacea have increased risk of dementia. Annals of Neurology, 2016, 79, 921-928.	5.3	41
236	Neonatal risk factors of atopic dermatitis in Denmark – Results from a nationwide registerâ€based study. Pediatric Allergy and Immunology, 2016, 27, 368-374.	2.6	33
237	Relation of Periodontitis to Risk of Cardiovascular and All-Cause Mortality (from a Danish) Tj ETQq1 1 0.784314	rgBT /Over 1.6	lock 10 Tf 50
238	Family history predicts major adverse cardiovascular events (MACE) in young adults with psoriasis. Journal of the American Academy of Dermatology, 2016, 75, 340-346.	1.2	15
239	Skin cancer in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1349-1353.	2.4	44
240	Association of Rosacea With Risk for Glioma in a Danish Nationwide Cohort Study. JAMA Dermatology, 2016, 152, 541.	4.1	33
241	Exploring the Association Between Rosacea and Parkinson Disease. JAMA Neurology, 2016, 73, 529.	9.0	95
242	Risk of Major Adverse Cardiovascular Events and All-Cause Mortality in Patients With Hidradenitis Suppurativa. JAMA Dermatology, 2016, 152, 429.	4.1	186
243	Clustering of autoimmune diseases in patients with rosacea. Journal of the American Academy of Dermatology, 2016, 74, 667-672.e1.	1.2	74
244	Patients with Rosacea Have Increased Risk of Depression and Anxiety Disorders: A Danish Nationwide Cohort Study. Dermatology, 2016, 232, 208-213.	2.1	81
245	Risk of Multiple Sclerosis in Patients withÂPsoriasis: A Danish Nationwide CohortÂStudy. Journal of Investigative Dermatology, 2016, 136, 93-98.	0.7	108
246	Association between depression and risk of atrial fibrillation and stroke in patients with psoriasis: a Danish nationwide cohort study. British Journal of Dermatology, 2015, 173, 471-479.	1.5	21
247	Risk of psoriasis in patients with childhood asthma: aÂDanish nationwide cohort study. British Journal of Dermatology, 2015, 173, 159-164.	1.5	15
248	Does treatment with statins protect against psoriasis?. British Journal of Dermatology, 2015, 173, 327-328.	1.5	0
249	Does systemic antipsoriatic therapy affect the cardiovascular risk?. British Journal of Dermatology, 2015, 173, 1362-1363.	1.5	0
250	Increased risk of migraine in patients with psoriasis: A Danish nationwide cohort study. Journal of the American Academy of Dermatology, 2015, 73, 829-835.	1.2	35
251	Association of Psoriatic Disease With Uveitis. JAMA Dermatology, 2015, 151, 1200.	4.1	59
252	Subtyp-spezifische Off-Label-Behandlung von Rosazea. Karger Kompass Dermatologie, 0, , 1-4.	0.0	0

#	Article	IF	CITATIONS
253	Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review. American Journal of Clinical Dermatology, 0, , .	6.7	7